Carlo Vancheri

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4847366/publications.pdf

Version: 2024-02-01

		57758	76900
134	6,370	44	74
papers	citations	h-index	g-index

138	138	138	8176
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. European Respiratory Journal, 2010, 35, 496-504.	6.7	399
2	The lung as a privileged site for the beneficial actions of PGE2. Trends in Immunology, 2004, 25, 40-46.	6.8	284
3	Effect of pirfenidone on proliferation, TGF-Î²-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. European Journal of Pharmaceutical Sciences, 2014, 58, 13-19.	4.0	281
4	The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 141.	3.6	199
5	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	10.7	198
6	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 356-363.	5.6	193
7	TGF-Î²1 targets the GSK-3Î²/Î²-catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacological Research, 2008, 57, 274-282.	7.1	180
8	Release of Mast-Cell-derived Mediators after Endobronchial Adenosine Challenge in Asthma. American Journal of Respiratory and Critical Care Medicine, 1995, 151, 624-629.	5.6	153
9	The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1426-1433.	6.7	146
10	Common pathways in idiopathic pulmonary fibrosis and cancer. European Respiratory Review, 2013, 22, 265-272.	7.1	143
11	Neutrophilâ€Toâ€Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Communityâ€Acquired Pneumonia. Journal of the American Geriatrics Society, 2017, 65, 1796-1801.	2.6	133
12	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	10.7	128
13	Inhibition of PI3K Prevents the Proliferation and Differentiation of Human Lung Fibroblasts into Myofibroblasts: The Role of Class I P110 Isoforms. PLoS ONE, 2011, 6, e24663.	2.5	126
14	Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2010, 5, e14003.	2.5	122
15	Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. Advances in Therapy, 2014, 31, 375-391.	2.9	115
16	Idiopathic pulmonary fibrosis: An update. Annals of Medicine, 2015, 47, 15-27.	3.8	97
17	Idiopathic pulmonary fibrosis and cancer: do they really look similar?. BMC Medicine, 2015, 13, 220.	5.5	92
18	Different Expression of TNF-Î± Receptors and Prostaglandin E₂Production in Normal and Fibrotic Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2000, 22, 628-634.	2.9	89

#	Article	IF	Citations
19	Qualitative European survey of patients with idiopathic pulmonary fibrosis: patientsâ€™ perspectives of the disease and treatment. BMC Pulmonary Medicine, 2016, 16, 10.	2.0	83
20	Cough in idiopathic pulmonary fibrosis. European Respiratory Review, 2016, 25, 278-286.	7.1	82
21	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	2.0	77
22	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	6.7	75
23	PI3K p110Î³ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Laboratory Investigation, 2013, 93, 566-576.	3.7	74
24	A progression-free end-point for idiopathic pulmonary fibrosis trials: lessons from cancer. European Respiratory Journal, 2013, 41, 262-269.	6.7	71
25	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	10.7	71
26	Idiopathic pulmonary fibrosis and lung cancer. Current Opinion in Pulmonary Medicine, 2015, 21, 626-633.	2.6	67
27	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine,the, 2018, 6, 86-88.	10.7	67
28	Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF), non-specific interstitial pneumonia (NSIP) and organ donors. Journal of Proteomics, 2013, 85, 109-128.	2.4	64
29	Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2001, 108, 703-708.	2.9	63
30	Protective effect of orally administered carnosine on bleomycin-induced lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L1095-L1104.	2.9	63
31	Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1701157.	6.7	61
32	Inhibition or knock out of Inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. Respiratory Research, 2005, 6, 58.	3.6	60
33	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	5.6	60
34	Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary SjÓ§gren's syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmunity Reviews, 2020, 19, 102447.	5.8	59
35	Chest imaging using signs, symbols, and naturalistic images: a practical guide for radiologists and non-radiologists. Insights Into Imaging, 2019, 10, 114.	3.4	59
36	Role of imaging in progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180073.	7.1	57

#	Article	IF	Citations
37	Idiopathic Pulmonary Fibrosis. Proceedings of the American Thoracic Society, 2012, 9, 153-157.	3.5	55
38	Clinical, serological and radiological features of a prospective cohort of Interstitial Pneumonia with Autoimmune Features (IPAF) patients. Respiratory Medicine, 2019, 150, 154-160.	2.9	53
39	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	1.9	53
40	The p53-homologue p63 may promote thyroid cancer progression. Endocrine-Related Cancer, 2005, 12, 953-971.	3.1	50
41	Effects of TGFâ€Î² and glucocorticoids on map kinase phosphorylation, ILâ€6/ILâ€11 secretion and cell proliferation in primary cultures of human lung fibroblasts. Journal of Cellular Physiology, 2007, 210, 489-497.	4.1	50
42	Resveratrol inhibits transforming growth factor-Î²â€“induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through ERK/Akt inhibition and PTEN restoration. Experimental Lung Research, 2011, 37, 162-174.	1.2	50
43	Utility of ultrasound assessment of diaphragmatic function before and after pulmonary rehabilitation in COPD patients. International Journal of COPD, 2018, Volume 13, 3131-3139.	2.3	50
44	The added value of comorbidities inÂpredicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. European Respiratory Journal, 2019, 53, 1801587.	6.7	50
45	Endothelin-1 induces proliferation of human lung fibroblasts and IL-11 secretion through an ETA receptor-dependent activation of map kinases. Journal of Cellular Biochemistry, 2005, 96, 858-868.	2.6	48
46	Altered intercellular communication in lung fibroblast cultures from patients with idiopathic pulmonary fibrosis. Respiratory Research, 2006, 7, 122.	3.6	47
47	State of the art in interstitial pneumonia with autoimmune features: a systematic review on retrospective studies and suggestions for further advances. European Respiratory Review, 2018, 27, 170139.	7.1	47
48	Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidisciplinary Respiratory Medicine, 2019, 14, 17.	1.5	43
49	Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Into Imaging, 2014, 5, 347-364.	3.4	42
50	Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy. Microorganisms, 2020, 8, 977.	3.6	41
51	Impact of intranasal budesonide on immune inflammatory responses and epithelial remodeling in chronic upper airway inflammation. Journal of Allergy and Clinical Immunology, 2003, 112, 37-44.	2.9	40
52	Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respiratory Research, 2006, 7, 137.	3.6	40
53	Altered Surfactant Homeostasis and Alveolar Epithelial Cell Stress in Amiodarone-Induced Lung Fibrosis. Toxicological Sciences, 2014, 142, 285-297.	3.1	40
54	When to start and when to stop antifibrotic therapies. European Respiratory Review, 2017, 26, 170053.	7.1	39

#	Article	IF	Citations
55	Bradykinin differentiates human lung fibroblasts to a myofibroblast phenotype via the B2 receptor. Journal of Allergy and Clinical Immunology, 2005, 116, 1242-1248.	2.9	37
56	Normal Human Lung Fibroblasts Differently Modulate Interleukin-10 and Interleukin-12 Production by Monocytes. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 592-599.	2.9	36
57	Human Upper Airway Epithelial Cell-Derived Granulocyte-Macrophage Colony-Stimulating Factor Induces Histamine-Containing Cell Differentiation of Human Progenitor Cells. International Archives of Allergy and Immunology, 1991, 95, 376-384.	2.1	34
58	The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak. Diagnostics, 2020, 10, 619.	2.6	33
59	16,16-Dimethyl Prostaglandin E2Efficacy on Prevention and Protection from Bleomycin-Induced Lung Injury and Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 50-58.	2.9	32
60	Protein profile of exhaled breath condensate determined by high resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2015, 105, 134-149.	2.8	32
61	Neural differentiation of human adiposeâ€derived mesenchymal stem cells induced by glial cell conditioned media. Journal of Cellular Physiology, 2018, 233, 7091-7100.	4.1	32
62	Lung CT Densitometry in Idiopathic Pulmonary Fibrosis for the Prediction of Natural Course, Severity, and Mortality. Chest, 2019, 155, 972-981.	0.8	32
63	New perspectives on management of idiopathic pulmonary fibrosis. Therapeutic Advances in Chronic Disease, 2016, 7, 108-120.	2.5	31
64	Differentiation of human adipose stem cells into neural phenotype by neuroblastomaâ€•or olfactory ensheathing cellsâ€conditioned medium. Journal of Cellular Physiology, 2013, 228, 2109-2118.	4.1	29
65	Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1702593.	6.7	29
66	Anti-inflammatory and antifibrotic effects of resveratrol in the lung. Histology and Histopathology, 2015, 30, 523-9.	0.7	29
67	Thymosin Î²4 protects <scp>C</scp>57<scp>BL</scp>/6 mice from bleomycinâ€induced damage in the lung. European Journal of Clinical Investigation, 2013, 43, 309-315.	3.4	28
68	Î²-Amyloid-Activated Cell Cycle in SH-SY5Y Neuroblastoma Cells: Correlation with the MAP Kinase Pathway. Journal of Molecular Neuroscience, 2004, 22, 231-236.	2.3	27
69	Patients with Interstitial Lung Disease Secondary to Autoimmune Diseases: How to Recognize Them?. Diagnostics, 2020, 10, 208.	2.6	27
70	HRCT Patterns of Drug-Induced Interstitial Lung Diseases: A Review. Diagnostics, 2020, 10, 244.	2.6	27
71	Inhibitory effect of a leukotriene receptor antagonist (montelukast) on neurokinin a-induced bronchoconstriction. Journal of Allergy and Clinical Immunology, 2003, 111, 833-839.	2.9	24
72	Thymosin Î²4 reduces IL-17-producing cells and IL-17 expression, and protects lungs from damage in bleomycin-treated mice. Immunobiology, 2014, 219, 425-431.	1.9	23

#	Article	IF	Citations
73	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Medicine, 2015, 13, 277.	5.5	23
74	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	2.6	22
75	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 156, 78-84.	2.9	21
76	Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 8812.	4.1	21
77	Cryptogenic Organizing Pneumonia: Evolution of Morphological Patterns Assessed by HRCT. Diagnostics, 2020, 10, 262.	2.6	21
78	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180078.	7.1	20
79	Assessment of survival in patients with idiopathic pulmonary fibrosis using quantitative HRCT indexes. Multidisciplinary Respiratory Medicine, 2018, 13, 43.	1.5	20
80	Interaction between human lung fibroblasts and T-lymphocytes prevents activation of CD4+ cells. Respiratory Research, 2005, 6, 103.	3.6	19
81	Translation and validation of the Kingâ€™s Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 2017, 14, 140-150.	2.4	19
82	Conditioned Media From Glial Cells Promote a Neural-Like Connexin Expression in Human Adipose-Derived Mesenchymal Stem Cells. Frontiers in Physiology, 2018, 9, 1742.	2.8	19
83	Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulmonary Medicine, 2019, 19, 213.	2.0	19
84	Stratification of long-term outcome in stable idiopathic pulmonary fibrosis by combining longitudinal computed tomography and forced vital capacity. European Radiology, 2020, 30, 2669-2679.	4.5	19
85	Nuclear factor-Îºb activation in human monocytes stimulated with lipopolysaccharide is inhibited by fibroblast conditioned medium and exogenous PGE2. FEBS Letters, 1997, 400, 315-318.	2.8	18
86	Preventive and therapeutic effects of thymosin Î²4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis. Oncotarget, 2016, 7, 33841-33854.	1.8	18
87	The Morphological Domain Does Not Affect the Rate of Progression to Defined Autoimmune Diseases in Patients With Interstitial Pneumonia With Autoimmune Features. Chest, 2020, 157, 238-242.	0.8	18
88	Protective effects of thymosin Î²4 in a mouse model of lung fibrosis. Annals of the New York Academy of Sciences, 2012, 1269, 69-73.	3.8	17
89	Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement. Multidisciplinary Respiratory Medicine, 2018, 13, 39.	1.5	17
90	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	7.1	17

#	Article	IF	Citations
91	Activation of cytosolic phospholipase A2 and 15-lipoxygenase by oxidized low-density lipoproteins in cultured human lung fibroblasts. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 522-532.	2.4	16
92	Effects of thymosin Î²4 and its N-terminal fragment Ac-SDKP on TGF-Î²-treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis. Expert Opinion on Biological Therapy, 2015, 15, 211-221.	3.1	16
93	Astrocytes Modify Migration of PBMCs Induced by Î²-Amyloid in a Blood-Brain Barrier in vitro Model. Frontiers in Cellular Neuroscience, 2019, 13, 337.	3.7	15
94	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	2.9	15
95	Evolution and treatment of idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104025.	1.9	15
96	Nailfold Videocapillaroscopy Is a Useful Tool to Recognize Definite Forms of Systemic Sclerosis and Idiopathic Inflammatory Myositis in Interstitial Lung Disease Patients. Diagnostics, 2020, 10, 253.	2.6	14
97	Suggestions for lung function testing in the context of COVID-19. Respiratory Medicine, 2021, 177, 106292.	2.9	14
98	Comorbidities of IPF: How do they impact on prognosis. Pulmonary Pharmacology and Therapeutics, 2018, 53, 6-11.	2.6	13
99	Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. Frontiers in Pharmacology, 2021, 12, 790204.	3.5	13
100	Quantum-inspired minimum distance classification in a biomedical context. International Journal of Quantum Information, 2018, 16, 1840011.	1.1	12
101	Clinical and radiological features of lung disorders related to connective-tissue diseases: a pictorial essay. Insights Into Imaging, 2022, 13, .	3.4	12
102	Montelukast protects against bradykinin-induced bronchospasm. Journal of Allergy and Clinical Immunology, 2005, 115, 870-872.	2.9	11
103	Astrocyte-like cells as a main target for estrogen action during neuronal differentiation. Molecular and Cellular Neurosciences, 2007, 34, 562-570.	2.2	9
104	Subsegmental Pulmonary Embolism: Value of Thoracic Ultrasound for Diagnosis and Follow-Up. Internal Medicine, 2008, 47, 1415-1417.	0.7	9
105	Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. Npj Primary Care Respiratory Medicine, 2018, 28, 10.	2.6	9
106	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1901188.	6.7	9
107	Resumption of respiratory outpatient services in the COVID-19 era: Experience from Southern Italy. American Journal of Infection Control, 2020, 48, 1087-1089.	2.3	9
108	The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy and Asthma Proceedings, 2005, 26, 292-8.	2.2	9

#	Article	IF	Citations
109	Antiproliferative effects induced by guanine-based purines require hypoxanthine-guanine phosphoribosyltransferase activity. Biological Chemistry, 2010, 391, 1079-89.	2.5	8
110	Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. Journal of Clinical Medicine, 2021, 10, 2548.	2.4	8
111	IPF, comorbidities and management implications. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2015, 32 Suppl 1, 17-23.	0.2	8
112	Exhaled bronchial cysteinyl leukotrienes in allergic patients. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 25-31.	2.3	6
113	Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. Respiratory Medicine Case Reports, 2019, 26, 126-130.	0.4	6
114	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology, 2020, 25, 1144-1151.	2.3	6
115	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	2.9	6
116	Mitogenic Effect of Nerve Growth Factor (NGF) in LNCaP Prostate Adenocarcinoma Cells: Role of the High- and Low-Affinity NGF Receptors. Molecular Endocrinology, 2000, 14, 124-136.	3.7	6
117	Nintedanib in IPF: Post hoc Analysis of the Italian FIBRONET Observational Study. Respiration, 2022, 101, 577-584.	2.6	6
118	Cystic Interstitial Lung Diseases: A Pictorial Review and a Practical Guide for the Radiologist. Diagnostics, 2020, 10, 346.	2.6	5
119	"Usual" interstitial pneumonia with autoimmune features: a prospective study on a cohort of idiopathic pulmonary fibrosis patients. Clinical and Experimental Rheumatology, 0, , .	0.8	5
120	A New Method for the Assessment of Myalgia in Interstitial Lung Disease: Association with Positivity for Myositis-Specific and Myositis-Associated Antibodies. Diagnostics, 2022, 12, 1139.	2.6	5
121	Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction. Respiratory Medicine, 2010, 104, 1417-1424.	2.9	4
122	Human lung fibroblasts increase CD4(+)CD25(+)Foxp3(+) T cells in co-cultured CD4(+) lymphocytes. Cellular Immunology, 2013, 285, 55-61.	3.0	4
123	Quantification of Ground Glass Opacities Can Be Useful to Describe Disease Activity in Systemic Sclerosis. Diagnostics, 2020, 10, 225.	2.6	4
124	Assessment of Lung Cancer Development in Idiopathic Pulmonary Fibrosis Patients Using Quantitative High-Resolution Computed Tomography. Journal of Thoracic Imaging, 2020, 35, 115-122.	1.5	3
125	Reply to: Malnutrition in idiopathic pulmonary fibrosis: the great forgotten comorbidity!. European Respiratory Journal, 2019, 53, 1900615.	6.7	2
126	Morphological Patterns of Sarcoidosis and Clinical Outcome: Retrospective Analysis through a Multidisciplinary Approach. Diagnostics, 2020, 10, 212.	2.6	2

#	Article	IF	Citations
127	Quantitative Evaluation of Fibrosis in IPF Patients: Meaning of Diffuse Pulmonary Ossification. Diagnostics, 2021, 11, 113.	2.6	2
128	Multidisciplinary Approach to Interstitial Lung Diseases: Nothing Is Better than All of Us Together. Diagnostics, 2020, 10, 488.	2.6	1
129	Rethinking Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2021, 42, 263-273.	2.1	1
130	Bradykinin and Tachykinin-induced Leukotriene Release in Airway Virus Infections. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 511-511.	5.6	1
131	Pathobiology of Novel Approaches to Treatment. , 2018, , 25-37.		0
132	PerFECT 2.0: A Web-Based Platform Designed to Facilitate and Support the Diagnosis of Patients with Idiopathic Pulmonary Fibrosis in Italy. Pulmonary Therapy, 2021, 7, 267-279.	2.2	0
133	Identifying the Risk of Acute Exacerbation in Idiopathic Pulmonary Fibrosis: Another Step Forward. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
134	"Usual" interstitial pneumonia with autoimmune features: a prospective study on a cohort of idiopathic pulmonary fibrosis patients.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0